Study guide
2.2 Chronic Kidney Disease
DHA Healthcare Professional Licensing Assessment - General Practitioner/Doctor Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Chronic Cardiovascular & Endocrine Disorders
1.1 Hypertension Management in Primary Care 1.2 Type 2 Diabetes Mellitus Management 1.3 Dyslipidemia & Thyroid Disorders
2 Chapter 2: Chronic Respiratory, Renal & Musculoskeletal Disorders
2.1 Asthma & COPD Maintenance 2.2 Chronic Kidney Disease 2.3 Chronic Musculoskeletal & Rheumatological Conditions
3 Chapter 3: Acute & Common Medical Problems
3.1 Common Infections in Primary Care 3.2 Anemia & Hematological Disorders 3.3 Acute Neurological Problems 3.4 Common Gastrointestinal Complaints
4 Chapter 4: Emergency Problems & Resuscitation
4.1 Cardiopulmonary Resuscitation & Shock 4.2 Acute Metabolic & Toxicological Emergencies 4.3 Trauma Assessment & Environmental Emergencies
5 Chapter 5: Common Pediatric Problems
5.1 Acute Pediatric Respiratory Infections 5.2 Febrile Seizures & Childhood Dehydration 5.3 Neonatal Jaundice & Pediatric Developmental Milestones
6 Chapter 6: Women's Health & Obstetric Care
6.1 Antenatal Care, Pre-eclampsia & Gestational Diabetes 6.2 Contraception & Menopause 6.3 Common Gynecological Conditions
7 Chapter 7: Common Surgical Problems
7.1 Acute Abdomen 7.2 Hernias, Hemorrhoids & Testicular Torsion 7.3 Abdominal Aortic Aneurysm & Urological Emergencies
8 Chapter 8: Common Psychiatric Problems
8.1 Mood & Anxiety Disorders 8.2 Psychosis, Delirium & Substance Use 8.3 Suicide Risk Assessment & Crisis Intervention
9 Chapter 9: Common Eye & ENT Problems
9.1 Acute Red Eye, Glaucoma & Uveitis 9.2 Otitis Media, Epistaxis & Vertigo 9.3 Common Upper Respiratory ENT Infections
10 Chapter 10: Common Dermatology Problems
10.1 Acne & Psoriasis 10.2 Eczema, Dermatitis & Skin Infections 10.3 Skin Infestations & Cutaneous Malignancies
11 Chapter 11: Family Medicine Concepts & Health Promotion
11.1 Patient-Centered Care & Continuity 11.2 Immunization & Travel Medicine 11.3 Smoking Cessation & Lifestyle Medicine
12 Chapter 12: Screening & Preventive Medicine
12.1 Cancer Screening 12.2 Cardiovascular & Metabolic Risk Screening
13 Chapter 13: Epidemiology, EBM, Ethics & UAE Regulations
13.1 Basic Epidemiology & Outbreak Measures 13.2 Evidence-Based Medicine & Study Designs 13.3 Professionalism, Ethics & UAE Regulations
2.2 Chronic Kidney Disease
Key Takeaways Explain This Topic AI
CKD is staged based on GFR (G1 to G5) and Albumin-to-Creatinine Ratio (ACR; A1 to A3), where ACR ≥ 30 mg/g defines pathological albuminuria.
ACE inhibitors or ARBs are the first-line renoprotective and antihypertensive agents in CKD patients with ACR ≥ 30 mg/g; combining them is strictly contraindicated.
SGLT2 inhibitors are recommended in patients with type 2 diabetes and CKD (eGFR down to 20 mL/min/1.73 m²), acting via tubuloglomerular feedback to constrict afferent arterioles.
Anemia of CKD is managed with iron repletion (target TSAT > 20%, ferritin > 100 ng/mL) prior to starting Erythropoiesis-Stimulating Agents, targeting a hemoglobin of 10-11.5 g/dL.
Secondary hyperparathyroidism in CKD-MBD is driven by phosphate retention and hypocalcemia (from low 1-alpha-hydroxylase activity), treated with dietary restriction and phosphate binders.
Last updated: July 2026
- Section 2.2: Chronic Kidney Disease
- 1. Definition, Staging, and Monitoring
Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function, present for more than 3 months, with implications for health. It is diagnosed by the presence of kidney damage markers (such as persistent albuminuria) or an estimated Glomerular Filtration Rate (eGFR) < 60 mL/min/1.73 m² for at least 3 months.
Staging Framework
The KDIGO (Kidney Disease: Improving Global Outcomes) classification system utilizes a dual-staging framework based on GFR (G-stage) and Albuminuria (A-stage).
- GFR Categories (G-stage)
- G1 : eGFR ≥ 90 mL/min/1.73 m² (Normal or high)
- G2 : eGFR 60-89 mL/min/1.73 m² (Mildly decreased)
- G3a : eGFR 45-59 mL/min/1.73 m² (Mildly to moderately decreased)
- G3b : eGFR 30-44 mL/min/1.73 m² (Moderately to severely decreased)
- G4 : eGFR 15-29 mL/min/1.73 m² (Severely decreased)
- G5 : eGFR < 15 mL/min/1.73 m² (Kidney failure; dialysis-dependent or requiring transplantation)
- Albuminuria Categories (A-stage)
Measured via a random spot urine albumin-to-creatinine ratio (ACR):
- A1 : ACR < 30 mg/g or < 3 mg/mmol (Normal to mildly increased)
- A2 : ACR 30-300 mg/g or 3-30 mg/mmol (Moderately increased; historically termed microalbuminuria)
- A3 : ACR > 300 mg/g or > 30 mg/mmol (Severely increased; historically termed macroalbuminuria)
The combination of G-stage and A-stage predicts the risk of CKD progression, cardiovascular events, and all-cause mortality, forming the KDIGO Heat Map. Patients with lower eGFR and higher albuminuria require more frequent clinical monitoring (ranging from once yearly for G1/A1 to four or more times yearly for G4/A3).
2. Diabetic Nephropathy and Renoprotective Strategies
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) globally.
Pathophysiology
Chronic hyperglycemia drives the production of advanced glycation end-products (AGEs) and activates inflammatory cytokines, leading to:
Glomerular Hyperfiltration : Driven by afferent arteriole vasodilation and efferent arteriole vasoconstriction.
Mesangial Expansion and Glomerular Basement Membrane (GBM) Thickening .
Nodular Glomerulosclerosis : Pathognomonic Kimmelstiel-Wilson nodules on histopathology.
This progression leads to protein leakage, starting as microalbuminuria (A2) and progressing to overt nephrotic-range proteinuria.
Renoprotective Pharmacotherapy
Renin-Angiotensin-Aldosterone System (RAAS) Blockade :
Indications : Angiotensin-Converting Enzyme Inhibitors (ACEi; e.g., ramipril, enalapril) or Angiotensin II Receptor Blockers (ARBs; e.g., losartan, valsartan) are indicated for all hypertensive CKD patients with an ACR ≥ 30 mg/g.
Mechanism : They selectively dilate the efferent arteriole , which decreases intraglomerular hydrostatic pressure, thereby reducing proteinuria and slowing the rate of GFR decline.
Monitoring : Serum creatinine and potassium must be checked 1-2 weeks after starting or increasing the dose. A serum creatinine increase of up to 30% from baseline is expected and acceptable due to altered hemodynamics. If the increase exceeds 30%, or if hyperkalemia is severe (K+ > 5.5 mEq/L) and refractory, the dose should be reduced or discontinued, and the patient evaluated for renal artery stenosis. Do not combine an ACEi and an ARB , as dual blockade increases the risk of acute kidney injury and hyperkalemia without adding clinical benefit.
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors :
Indications : SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) are recommended in patients with type 2 diabetes, CKD, and an eGFR ≥ 20-25 mL/min/1.73 m² (and ACR ≥ 200 mg/g).
Mechanism : By blocking sodium-glucose reabsorption in the proximal tubule, they increase sodium delivery to the macula densa. This restores tubuloglomerular feedback, leading to afferent arteriole vasoconstriction , lowering intraglomerular pressure, and providing potent cardiorenal protection.
Blood Pressure Target :
KDIGO recommends a target systolic blood pressure < 120 mmHg using standardized office blood pressure measurement, unless contraindicated by side effects like orthostatic hypotension.
3. Staging Complications and Clinical Management
As kidney function declines, complications emerge and must be managed aggressively.
Anemia of CKD
Principally caused by a deficiency in renal erythropoietin (EPO) production.
Diagnosis : Checked when hemoglobin (Hb) falls below 12 g/dL in adult females and 13 g/dL in adult males.
Iron Assessment : Prior to starting Erythropoiesis-Stimulating Agents (ESAs; e.g., epoetin alfa, darbepoetin alfa), iron stores must be repleted. The target is a transferrin saturation ( TSAT) > 20% and serum ferritin > 100 ng/mL in non-dialysis patients (ferritin > 200 ng/mL in dialysis patients). Repletion is achieved via oral or intravenous iron.
ESA Therapy : Initiated when Hb is < 10 g/dL. The therapeutic target is 10-11.5 g/dL . Target levels > 11.5 g/dL (or normalized Hb) are avoided because clinical trials demonstrated they do not improve outcomes and instead increase the risk of stroke, venous thromboembolism, and cardiovascular death.
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
CKD-MBD is a systemic disorder that links bone disease (renal osteodystrophy) and vascular calcification.
Pathophysiology :
Reduced GFR leads to hyperphosphatemia because of impaired renal phosphate excretion.
Loss of functional kidney tissue impairs 1-alpha-hydroxylase activity, preventing the conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol).
This deficiency in active vitamin D reduces intestinal calcium absorption, causing hypocalcemia .
Both hyperphosphatemia and hypocalcemia stimulate the parathyroid glands, leading to secondary hyperparathyroidism . High levels of PTH mobilize calcium from bone, leading to high-turnover bone disease (osteitis fibrosa cystica) and calciphylaxis.
Management :
Dietary Phosphate Restriction : Limit intake of high-phosphate foods (dairy, cola, processed foods).
Phosphate Binders : Taken with meals to bind dietary phosphate. Calcium-based binders (e.g., calcium carbonate, calcium acetate) are effective but carry a risk of hypercalcemia and vascular calcification. Non-calcium binders (e.g., sevelamer carbonate, lanthanum carbonate) are preferred in patients with pre-existing hypercalcemia, low PTH, or severe vascular/valvular calcification.
Vitamin D Therapy : Calcitriol (active vitamin D) or active analogs (e.g., paricalcitol) are used to suppress PTH.
Calcimimetics : Cinacalcet increases the sensitivity of calcium-sensing receptors on the parathyroid gland, decreasing PTH secretion without increasing serum calcium or phosphate.
Hyperkalemia and Volume Management
Hyperkalemia : Chronic hyperkalemia is managed with dietary potassium restriction, loop diuretics, and oral potassium binders (e.g., sodium zirconium cyclosilicate, patiromer).
Fluid Overload : Managed with loop diuretics (furosemide, torsemide, or bumetanide). In advanced CKD, high doses are required, and combination therapy with thiazide-like diuretics (e.g., metolazone) may be necessary to overcome diuretic resistance.